For the first time, newborn babies with malaria have a treatment designed specifically for them. Regulators have approved Coartem Baby, a dissolvable, cherry-flavored formulation of an existing antimalarial drug that is safe and correctly dosed for infants weighing less than 5 kilograms — a group that previously had no approved treatment at all.
At a glance
- Newborn malaria treatment: Coartem Baby is the first antimalarial drug approved specifically for infants under 5 kg, developed through a partnership between Novartis and the non-profit Medicines for Malaria Venture (MMV).
- Regulatory pathway: Swiss regulator Swissmedic granted approval, fast-tracking the process for eight African countries — Burkina Faso, Côte d’Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda — that participated in clinical trials.
- Access commitment: Novartis has pledged to provide the treatment on a largely not-for-profit basis, prioritizing availability in malaria-endemic regions where the need is greatest.
Why the youngest babies were left out
Until now, infants under 5 kilograms occupied a blind spot in malaria medicine. No approved drug existed for them, so caregivers and clinicians often relied on formulations designed for older, heavier children — a workaround that carried real risks of incorrect dosing and toxicity.
That gap has existed for decades, even as malaria killed hundreds of thousands of young children each year. According to the World Health Organization, children under five account for roughly three-quarters of all malaria deaths in Africa.
Newborns were also excluded from prevention tools like malaria vaccines, which are not approved for the youngest infants. Coartem Baby fills that gap directly, giving frontline health workers their first purpose-built option for their smallest patients.
How a public-private partnership made it happen
The development of Coartem Baby reflects a model of global health cooperation that is still relatively new. Novartis, a major pharmaceutical company, partnered with MMV, a non-profit focused on antimalarial drug development. Together, they worked out the precise dose and ingredient ratio safe for newborns — then designed a formulation those babies could actually take: dissolvable, sweet, and easy to administer.
The regulatory strategy was equally deliberate. By running clinical trials across eight African countries and seeking initial approval through Swissmedic, the partnership created a pathway for rapid national approvals in exactly the places where the drug is needed most. This kind of coordinated approach — linking research, regulation, and access — has historically been hard to achieve in global health.
It also echoes broader efforts to close equity gaps in medicine. Similar public-private structures have driven progress in other hard-to-treat populations, including landmark prevention trials for Alzheimer’s disease that once seemed out of reach.
What this means on the ground
Health workers in rural and remote communities bear most of the burden of diagnosing and treating malaria. Many operate with limited supplies and see the youngest, most fragile patients regularly. A drug that is correctly dosed, easy to give, and available at low cost changes what those workers can offer.
Malaria remains one of the most preventable causes of child death globally. Insecticide-treated bed nets and indoor spraying have reduced transmission significantly over the past two decades — a story of progress tracked across the broader arc of global health investment. Coartem Baby adds a new layer to that protection, specifically for the window of life when no treatment previously existed.
The CDC’s malaria program and WHO country-level strategies have long identified newborn and infant treatment as a priority gap. That gap now has an answer.
An honest look at what remains
Approval is a milestone, not a guarantee of impact. Getting Coartem Baby to the communities that need it will require sustained supply chains, trained health workers, and continued funding — none of which is automatic. The not-for-profit pricing commitment is a strong signal, but distribution infrastructure in some of the eight participating countries remains fragile, and broader rollout beyond those nations will take time.
Still, the existence of this drug — where none existed before — is a meaningful and measurable step forward for the world’s most vulnerable patients.
Read more
For more on this story, see: Good News for Humankind
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- Renewables now make up at least 49% of global power capacity
- The Good News for Humankind archive on global health
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
COP30 pledges recognition of 160 million hectares of Indigenous land rights
At the COP30 World Leaders Summit in Belém, Brazil in November 2025, 15 governments pledged to formally recognize Indigenous land rights over 160 million hectares by 2030 — an area the size of Iran — through the Intergovernmental Land Tenure Commitment. Brazil committed at least 59 million hectares. More than 35 donors renewed a $1.8 billion Forest and Land Tenure Pledge. The Tropical Forest Forever Facility secured nearly $7 billion, with 20% directed to Indigenous peoples. It was the largest Indigenous participation in COP history.
-
Ghana creates its first marine protected area to rescue depleted fish stocks
Ghana has declared its first marine protected area near Cape Three Points on the Gulf of Guinea, marking a historic step to reverse decades of overfishing. The protected zone aims to restore fish populations that have collapsed under pressure from industrial trawling and illegal fishing. The decision supports 2.7 million Ghanaians whose livelihoods depend on healthy coastal fisheries and aligns Ghana with the global goal of protecting 30 percent of the world’s oceans by 2030.
-
U.S. researchers cut Alzheimer’s risk by half in first-ever prevention trial
For the first time, researchers have evidence that removing amyloid plaques from the brain before symptoms appear can cut Alzheimer’s risk by roughly half. A clinical trial published in The Lancet Neurology, led by Washington University School of Medicine in St. Louis, found that long-term treatment with the antibody drug gantenerumab significantly delayed dementia onset in people with a rare genetic form of the disease. The findings provide the clearest signal yet that intervening years before symptoms emerge can change the course of Alzheimer’s disease.
